<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861223</url>
  </required_header>
  <id_info>
    <org_study_id>2012-11-087-007</org_study_id>
    <nct_id>NCT01861223</nct_id>
  </id_info>
  <brief_title>Afatinib Plus Nimotuzumb for NSCLC</brief_title>
  <official_title>A Phase Ib Study of Afatinib Plus Nimotuzumab in Non-small Cell Lung Cancer Patients Who Progressed With Reversible EGFR TKI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find the optimal dose of afatinib and nimotuzumab in patients who acquired resistance to
      gefitinib or erlotinib.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal tolerated dose</measure>
    <time_frame>4 weeks</time_frame>
    <description>To establish maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) for BIBW 2992 and nimotuzumab in patients with acquired resistance to erlotinib or gefitinib</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>afatinib + nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)</intervention_name>
    <arm_group_label>afatinib + nimotuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of stage IIIB or IV NSCLC

          -  Presence of EGFR sensitizing mutations (L858R mutation in exon 21 or exon 19 deletion)
             or response by RECIST on prior gefitinib or erlotinib or stable disease on prior
             gefitinib or erlotinib for at least 6 months

          -  Disease progression on treatemtn with gefitinib or erlotinib within 30 days

          -  Biopsy on disease progression

          -  Age ≥20 years

          -  ECOG performance status of 0, 1, or 2

          -  Measurable disease by the criteria of RECIST 1.1

          -  Adequate organ function as evidenced by the following; Absolute neutrophil count &gt; 1.5
             x 109/L; platelets &gt; 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or ALT &lt; 5 UNL;
             creatinine clearance ≥ 45 mL/min

        Exclusion Criteria:

          -  Known interstitial lung disease

          -  Prior treatment with EGFR targeting antibodies or BIBW 2992

          -  Prior three or more lines of chemotherapy for advanced NSCLC

          -  Significant bowel disease impairing drug absorption

          -  Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or
             arrhythmia

          -  Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases.
             Patients with treated CNS metastases are eligible provided their disease is
             radiographically stable, asymptomatic, and corticosteroid use has been discontinued
             for at least 2 weeks prior to the first dose of study drug. Screening of asymptomatic
             patients without history of CNS metastases is not required.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myung-Ju Ahn</last_name>
    <phone>822-3410-3459</phone>
    <email>silkahn@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ju Ahn</last_name>
    </contact>
    <investigator>
      <last_name>Jong-Mu Sun</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <last_update_submitted>February 23, 2014</last_update_submitted>
  <last_update_submitted_qc>February 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Myung-Ju Ahn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>acquired resistance</keyword>
  <keyword>gefitinib</keyword>
  <keyword>erlotinib</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

